Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

ClinicalTrials.gov ID: NCT03605862

Public ClinicalTrials.gov record NCT03605862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Study identification

NCT ID
NCT03605862
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Romark Laboratories L.C.
Industry
Enrollment
1,756 participants

Conditions and interventions

Interventions

  • Nitazoxanide Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 10, 2018
Primary completion
Feb 3, 2019
Completion
Feb 3, 2019
Last update posted
Apr 13, 2022

2018 – 2019

United States locations

U.S. sites
43
U.S. states
23
U.S. cities
39
Facility City State ZIP Site status
Vanguard Study Site Birmingham Alabama 35235
Vanguard Study Site Birmingham Alabama 35242
Vanguard Study Site Pelham Alabama 35124
Vanguard Study Site Hot Springs Arkansas 71913
Vanguard Study Site Anaheim California 92805
Vanguard Study Site Westminster California 92683
Vanguard Study Site Wilmington California 90744
Vanguard Study Site Miami Florida 33145
Vanguard Study Site Miami Florida 33155
Vanguard Study Site Miami Florida 33174
Vanguard Study Site Orlando Florida 32819
Vanguard Study Site Tampa Florida 33609
Vanguard Study Site Stockbridge Georgia 30281
Vanguard Study Site Blackfoot Idaho 83221
Vanguard Study Site Meridian Idaho 83642
Vanguard Study Site Nampa Idaho 83686
Vanguard Study Site Evanston Illinois 60201
Vanguard Study Site Valparaiso Indiana 46383
Vanguard Study Site Louisville Kentucky 40207
Vanguard Study Site New Orleans Louisiana 70115
Vanguard Study Site New Orleans Louisiana 70124
Vanguard Study Site Baltimore Maryland 21236
Vanguard Study Site St Louis Missouri 63141
Vanguard Study Site Missoula Montana 59808
Vanguard Study Site Bellevue Nebraska 68005
Vanguard Study Site Las Vegas Nevada 89104
Vanguard Study Site Brooklyn New York 11229
Vanguard Study Site Raleigh North Carolina 27607
Vanguard Study Site Cincinnati Ohio 45215
Vanguard Study Site Cleveland Ohio 44122
Vanguard Study Site Columbus Ohio 43214
Vanguard Study Site Dayton Ohio 45424
Vanguard Study Site Medford Oregon 97504
Vanguard Study Site East Providence Rhode Island 02914
Vanguard Study Site Jackson Tennessee 38305
Vanguard Study Site Milan Tennessee 38328
Vanguard Study Site Austin Texas 78735
Vanguard Study Site Carrollton Texas 75010
Vanguard Study Site Houston Texas 77058
Vanguard Study Site McAllen Texas 78504
Vanguard Study Site Plano Texas 75024
Vanguard Study Site Bountiful Utah 84010
Vanguard Study Site St. George Utah 84790

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03605862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 13, 2022 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03605862 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →